This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $340,685 to Serentrix LLC to develop a novel topical treatment for burn pain. The goal is to block the transient receptor potential vanilloid 1 (TRPV1) pain receptor in the skin using Serentrix's lead compound SER114, which has demonstrated success in Phase 1 clinical trials for neuropathic pain. By selectively targeting this key pain receptor present in the skin, the project aims to provide a topical formulation that can effectively treat cutaneous burn pain while reducing the risk of adverse effects compared to systemic treatments. The award period runs from August 1, 2024 to July 31, 2025.
Generated 3/18/25, 4:49 AM